Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02271243

Enrollment

Registered

2014-10-22

Start date

2014-11-01

Completion date

2027-12-01

Last updated

2026-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Line-associated Bloodstream Infections, Laboratory-confirmed Bloodstream Infection, Mucosal Barrier Injury

Keywords

Central line-associated bloodstream infections, mucosal barrier injury, laboratory-confirmed bloodstream infection

Brief summary

Central line-associated bloodstream infections (CLABSIs) are the most common healthcare-associated infection in children and are associated with morbidity and mortality. This study will attempt to identify the source of bloodstream infections (BSIs) in children with CLABSI because we hypothesize that many of the BSIs that are currently classified as CLABSIs are actually laboratory-confirmed bloodstream infections (LCBI) that may be a result of mucosal barrier injury (MBI), also known as MBI-LCBI. In order to study this, we will isolate bacteria from multiple body sites of children that have BSI in order to compare these bacteria to the strain growing in their blood using whole-genome DNA sequencing. We will also evaluate biomarkers of MBI of the respiratory tract and GI tract.

Detailed description

This is a prospective cohort pilot study at Boston Children's Hospital (BCH) that will explore the source of presumed CLABSI, which we believe may actually have multiple possible sources including MBI. We plan to enroll all inpatient children at BCH who meet the Centers for Disease Control and Prevention (CDC) definition of MBI-LCBI as well as children who meet the criteria for CLABSI without MBI. For all enrolled patients, we will collect samples from the oral cavity, respiratory tract, skin, and stool. These samples will be cultured in order to see if the same microbial species and strain(s) growing from the blood also grow from these other sites. Cultures will then have isolated colonies selected for whole-genome DNA sequencing to allow assessment of genomic diversity between body sites. Stool and blood samples will be tested for markers of MBI. All patient enrollment and sample collection will be done at BCH.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Hospitalized at Boston Children's Hospital * Central venous catheter of any type including peripherally inserted central catheters (PICC) in any location. * Laboratory-confirmed bloodstream infection (LCBI) diagnosed by a clinical blood culture growing certain Gram-negative rods

Exclusion criteria

* Patients with CDC-defined secondary bloodstream infections

Design outcomes

Primary

Measure	Time frame	Description
Phylogenetic relationships (on SNP scale) of bacteria isolated from different body sites	Up to 2 years	Phylogeny will be determined using whole-genome DNA sequences of multiple bacterial colonies that grow from each body site.

Secondary

Measure	Time frame	Description
Levels of biomarkers of MBI in the blood and stool (citrulline in blood, calprotectin in stool)	Up to 2 years	Low citrulline and high calprotectin indicate GI tract mucosal barrier injury.

Countries

United States

Contacts

CONTACTRachel Bernier, MPH

Rachel.Bernier@childrens.harvard.edu857-218-5348

PRINCIPAL_INVESTIGATORGregory Priebe, MD

Boston Children's Hospital

Outcome results